AzTrials
AzTrials

PresbyopiaNCT03417557

Clinical Validation Study of Comfilcon A Multifocal Toric Contact Lenses

A study testing Comfilcon A lens (test) in people with Presbyopia, run by CooperVision, Inc. at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This is a study to evaluate the clinical performance and subjective acceptance of an investigational contact lens (test), compared to a marketed lens (control) in an in-office setting. Read more about this study

Who is it for?
Ages 40 to 75 years
Conditions the study is for
Presbyopia
What is being tested?
Comfilcon A lens (test)
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
20 participants
Where
1 siteUnited States
Study dates
12 Jan 2018to 3 Apr 2018
Phase
Interventional
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 40 to 75 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Has had a self-reported oculo-visual examination in the last two years.
  • Is between ages 40-75 years, inclusive and has full legal capacity to volunteer.
  • Has read and understood the information consent letter. Is willing and able to follow instructions and maintain the appointment schedule.
  • Is able to participate in Parts A and B related to this work.
  • Has a contact lens spherical prescription between +10.00 to 10.00D (inclusive).
  • Has an Add component to their spectacle refraction (between +0.75 and +2.50DS).
Show all 11Show fewer
  • Has astigmatism between of -0.75 and -5.75DC (based on the calculated ocular refraction) in each eye.
  • Is correctable to a visual acuity of 20/40 or better (in each eye) with their habitual vision correction or 20/25 best-corrected.
  • Currently wears soft contact lenses.
  • Has clear corneas and no active ocular disease.
  • Has not worn lenses for at least 12 hours before the examination.

Who cannot join

  • A person will be excluded from the study if he/she:
  • Has never worn contact lenses before.
  • Has any systemic disease affecting ocular health.
  • Is using any systemic or topical medications that will affect ocular health.
  • Has any ocular pathology or severe insufficiency of lacrimal secretion (moderate to severe dry eyes) that would affect the wearing of contact lenses.
  • Has persistent, clinically significant corneal or conjunctival staining using sodium fluorescein dye.
Show all 10Show fewer
  • Has any clinically significant lid or conjunctival abnormalities, active neovascularization or any central corneal scars.
  • Is aphakic.
  • Has undergone corneal refractive surgery.
  • Is participating in any other type of eye related clinical or research study.

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Clinical Optics Research Lab (CORL) Indiana University School of Optometry, Indiana University

    Bloomington, Indiana, 47405

Other trials in United States

About this study

Official title: Clinical Validation Study of Biofinity Multifocal Toric Contact Lenses

This is a study to evaluate the clinical performance and subjective acceptance of an investigational contact lens (test), compared to a marketed lens (control) in an in-office setting.

Read the detailed description

This is a study to evaluate the clinical performance (including visual acuity, subjective assessments of visual performance, comfort ratings, vision preference and lens fit) of a comfilcon A investigational contact lens (test) compared to a control contact lens, in a non-dispensing setting. The main study hypothesis is the test contact lens will not be clinically inferior to the control lens.

Conditions
Presbyopia
Being tested
Comfilcon A lens (test), Omafilcon B lens (control)
Medical subject headings
Presbyopia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Comfilcon A lens (test)Device

    Also called Biofinity multifocal toric Lens (test)

    contact lens

  • Omafilcon B lens (control)Device

    Also called Proclear multifocal toric lens (control)

    contact lens

Study groups in NCT03417557
Study groupRoleWhat they receive
Comfilcon A lens (test)ExperimentalSubjects are randomized to wear comfilcon A lens for up to 3 hours, either as first or second lens during this cross over study.
Receives: Device: Comfilcon A lens (test)
Omafilcon B Lens (control)Active comparatorSubjects are randomized to wear omafilcon B lens for up to 3 hours, either as first or second lens during this cross over study.
Receives: Device: Omafilcon B lens (control)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Visual Acuity

    Visual acuity is assessed for test and control lens on a logMAR chart

    Measured: up to 3 hours

Secondary outcomes (3)
  1. Subjective Assessment of Visual Performance: Distance Day-time Navigation Tasks for Vision Quality and Clarity

    Subjective assessment of visual performance for distance day-time navigation tasks for vision/clarity was assessed for test and control lens at different testing distances. Scale 0-100, 0=poor, 100=excellent.

    Measured: up to 3 hours

  2. Subjective Assessment of Visual Performance: Intermediate / Computer Task for Vision Quality and Clarity

    Subjective assessments of visual performance for intermediate / computer tasks for vision quality and clarity were assessed for test and control lens at different testing distances. Scale 0-100, 0=poor, 100=excellent.

    Measured: up to 3 hours

  3. Subjective Assessment of Visual Performance: Near Vision for Vision Quality and Clarity

    Subjective assessments of visual performance for near vision was assessed for vision quality and clarity for test and control lens at different testing distances. Scale 0-100, 0=poor, 100=excellent.

    Measured: up to 3 hours

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted31 Jan 2018
  2. Study start12 Jan 2018
  3. Primary completion3 Apr 2018
  4. Study completion3 Apr 2018

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Crossover
Model description
This will be, prospective, single-masked, randomized, bilateral, cross-over, non-dispensing study comparing the test lens against the control lens.
Masking
Single blind
Who is masked
Participant
Enrolment
20 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03417557
Sponsor's protocol ID
CV-18-10
Status last verified
Apr 2020
First submitted
25 Jan 2018
Last updated
4 May 2020
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Comfilcon A lens (test) in people with Presbyopia, run by CooperVision, Inc. at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 11 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 4 May 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 4 May 2020). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Visual Acuity (time frame: up to 3 hours). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 May 2020.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in